Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03447886 · ClinicalTrials.gov registry record
Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 17
- Enrollment target
NCT03447886: Completed study, sponsored by Dana-Farber Cancer Institute.
NCT03447886 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03447886 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 17 participants
- Enrollment target
Study Summary
The overall goal of this study is to qualitatively explore how behavioral, cultural, psychosocial, and economic barriers and facilitators affect the decision to start and adhere to endocrine therapy (ET) among young breast cancer survivors of diverse racial, ethnic, and socio-economic backgrounds with hormone receptor positive (HR+) breast cancer
Primary Outcome
Open ended questions
Interventions
- OTHER Phone interview
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-03-09 |
| Est. Completion | 2018-08-27 |
What the finished NCT03447886 record still lists
NCT03447886 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 17 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Phone interview is the first listed.
NCT03447886 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03447886 about?
NCT03447886 is a clinical study titled "Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds". The overall goal of this study is to qualitatively explore how behavioral, cultural, psychosocial, and economic barriers and facilitators affect the decision to start and adhere to endocrine therapy (ET) among young breast cancer survivors of diverse racial, ethnic, and socio-economic backgrounds wi...
What is the current status of trial NCT03447886?
This trial is currently completed. The enrollment target is 17 participants. The study started on 2018-03-09. Estimated completion is 2018-08-27.
What interventions are being tested in trial NCT03447886?
The interventions under investigation include: Phone interview (OTHER).
Who is sponsoring clinical trial NCT03447886?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI